Showing results (221-230 of 268) with videos related to
Sort By:
Pageof 27
Radiation Oncology (London, England)|April 4, 2024
Impact of FAPI-46/dual-tracer PET/CT imaging on radiotherapeutic management in esophageal cancerSimone Wegen, Karina Claus, Philipp Linde, et al.Plos One|December 17, 2008
Early detection of erlotinib treatment response in NSCLC by 3'-deoxy-3'-[F]-fluoro-L-thymidine ([F]FLT) positron emission tomography (PET)Roland T Ullrich, Thomas Zander, Bernd Neumaier, et al.British Journal of Cancer|November 1, 2018
Tumour-infiltrating neutrophils counteract anti-VEGF therapy in metastatic colorectal cancerLars Mortimer Schiffmann, Melanie Fritsch, Florian Gebauer, et al.Oncoimmunology|July 29, 2016
PD-L1 expression in non-small cell lung cancer: Correlations with genetic alterationsAndreas H Scheel, Sascha Ansén, Anne M Schultheis, et al.Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|October 20, 2009
Downregulation of 18F-FDG uptake in PET as an early pharmacodynamic effect in treatment of non-small cell lung cancer with the mTOR inhibitor everolimusLucia Nogová, Ronald Boellaard, Carsten Kobe, et al.Scientific Reports|October 10, 2018
Somatic alterations in circulating cell-free DNA of oesophageal carcinoma patients during primary staging are indicative for post-surgical tumour recurrenceHelen Pasternack, Jana Fassunke, Patrick Sven Plum, et al.Plos One|May 17, 2011
Benchmarking of mutation diagnostics in clinical lung cancer specimensSilvia Querings, Janine Altmüller, Sascha Ansén, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 12, 2011
Blood-based gene expression signatures in non-small cell lung cancerThomas Zander, Andrea Hofmann, Andrea Staratschek-Jox, et al.Cancer Immunology, Immunotherapy : CII|October 2, 2020
Microwave ablation enhances tumor-specific immune response in patients with hepatocellular carcinomaKatharina Leuchte, Elena Staib, Martin Thelen, et al.Gut|May 24, 2015
Activating ERBB2/HER2 mutations indicate susceptibility to pan-HER inhibitors in Lynch and Lynch-like colorectal cancerMichael Kloth, Vanessa Ruesseler, Christoph Engel, et al.Pageof 27